Business Context and Reporting Period
This Form 8-K Current Report was filed by Neoleukin Therapeutics, Inc. (trading symbol: NLTX) on April 3, 2023. The report details significant changes in executive leadership effective March 31, 2023, including the resignation of the former CEO and the appointment of interim officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Executive Resignation: Dr. Jonathan Drachman, M.D., resigned as President, Chief Executive Officer, principal executive and financial officer, and director effective March 31, 2023.
- Interim Appointments:
- Donna M. Cochener appointed Interim Chief Executive Officer and principal executive officer.
- Sean Smith appointed Interim Chief Financial Officer and principal financial officer.
- Departure of Chief Medical Officer: Dr. Priti Patel entered into a Separation Agreement effective March 31, 2023.
Compensation, Risks, and Contingencies
Interim Executive Compensation
- Base Salaries: Donna M. Cochener ($450,000) and Sean Smith ($410,000).
- 2023 Annual Bonus: Minimum of $219,375 for Ms. Cochener and $159,167 for Mr. Smith, prorated if terminated early.
- Retention Bonus: $219,375 for Ms. Cochener and $159,167 for Mr. Smith, payable upon Change of Control, termination without Cause, resignation for Good Reason, or December 31, 2023.
- Severance (Outside Change of Control): 9 months of salary continuation and 9 months of COBRA benefits.
- Severance (Within Change of Control Window): 15 months of salary, 125% of annual bonus, 15 months of COBRA, acceleration of equity awards, and extended option exercise periods.
Dr. Priti Patel Separation Terms
- Severance: 9 months of base salary continuation and 9 months of healthcare premium payments.
- Retention Payment: Lump sum equal to 50% of salary earned in fiscal year 2023 through the separation date.
- Equity Acceleration: 100% vesting of 100,000 shares from the August 2022 option grant and acceleration of unvested RSUs originally scheduled to vest April 30, 2023.
- Option Extension: 12-month post-termination exercise period for vested options.
Risks and Contingencies: All severance and retention payments are conditioned on the execution of a standard release of claims. The filing notes that the summary of agreements is subject to the full text of the Employment Agreements and Separation Agreement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement Amendments and Separation Agreement in the upcoming Form 10-Q for the quarter ended March 31, 2023.
- Confirm the status of the search for a permanent Chief Executive Officer and Chief Financial Officer.
- Assess the impact of the departure of the Chief Medical Officer on the company's clinical development pipeline.
- Review the company's cash runway given the immediate cash outflows for severance and retention payments.